UroGen Pharma is trading 4.86% down now at $38.72, with no clear company-specific announcement explaining the move.

  • A recent UroGen investor conference transcript discusses its UGN-103 FDA submission, but it is not an October 8 announcement.
  • Broader markets are under pressure amid rising yields and oil-related concerns, while the provided sector context says healthcare is up 1.25%.
  • No direct macro link to this stock was established.